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Abstract
Background: In the Netherlands, 5.6 % of acute hospital admissions are medication-related. Almost half of these
admissions are potentially preventable. Reviewing medication in patients at risk in primary care might prevent these
hospital admissions. At present, implementation of medication reviews in primary care is suboptimal: pharmacists
lack access to patient information, pharmacists are short of clinical knowledge and skills, and working processes of
pharmacists (focus on dispensing) and general practitioners (focus on clinical practice) match poorly. Integration of
the pharmacist in the primary health care team might improve pharmaceutical care outcomes.
The aim of this study is to evaluate the effect of integration of a non-dispensing pharmacist in general practice on
the safety of pharmacotherapy in the Netherlands.
Methods: The POINT study is a non-randomised controlled intervention study with pre-post comparison in an
integrated primary care setting. We compare three different models of pharmaceutical care provision in primary
care: 1) a non-dispensing pharmacist as an integral member of a primary care team, 2) a pharmacist in a community
pharmacy with a predefined training in performing medication reviews and 3) a pharmacist in a community
pharmacy (care as usual). In all models, GPs remain accountable for individual medication prescription. In the first
model, ten non-dispensing clinical pharmacists are posted in ten primary care practices (including 5 – 10 000
patients each) for a period of 15 months. These non-dispensing pharmacists perform patient consultations,
including medication reviews, and share responsibility for the pharmaceutical care provided in the practice.
The two other groups consist of ten primary care practices with collaborating pharmacists. The main outcome
measurement is the number of medication-related hospital admissions during follow-up. Secondary outcome
measurements are potential medication errors, drug burden index and costs. Parallel to this study, a qualitative
study is conducted to evaluate the feasibility of introducing a NDP in general practice.
Discussion: As the POINT study is a large-scale intervention study, it should provide evidence as to whether integration
of a non-dispensing clinical pharmacist in primary care will result in safer pharmacotherapy. The qualitative study also
generates knowledge on the optimal implementation of this model in primary care. Results are expected in 2016.
Trial registration number: NTR4389, The Netherlands National Trial Register, 07-01-2014.
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Background
Adverse drug events account for 5,6 % of acute hospital
admissions in the Netherlands. Almost half of these
admissions are potentially preventable [1]. Older age,
polypharmacy, multimorbidity, impaired cognition and
impaired renal function have been identified as risk fac-
tors for these preventable medication-related hospital
admissions (HARMs) [1]. Given the ageing of the popu-
lation, the population at risk will grow in near future.
Hence, new strategies are needed to improve the effect-
iveness and safety of pharmacotherapy in clinical prac-
tice and to prevent these hospital admissions.
As most of the pharmacotherapy is initiated in general
practice, its quality may be primarily improved by struc-
tural reviewing patients’ medication in primary care. So
far, the results of studies on the effectiveness of medica-
tion reviews have been inconclusive: several studies re-
ported a positive effect on the number of drug therapy
problems [2–7], but no effect on morbidity, mortality or
quality of life was found.
Several difficulties hamper the implementation of
medication reviews in primary care [8–10] and may have
contributed to the inconclusiveness of these results. First
of all, as community pharmacists get no or an insuffi-
cient fee for performing medication reviews, a financial
incentive is lacking. However, this does not seem to be
the only problem. Another important difficulty in the
implementation is the lack of information: community
pharmacists do not have access to routine patient re-
cords. Consequently, performing proper medication re-
views is often impeded, as not all available information
can be taken into account. Third, pharmacists lack
clinical pharmacology knowledge and clinical reasoning
skills, for pharmaceutical training and practice are his-
torically drug product oriented instead of patient ori-
ented. Community pharmacists’ tasks mainly concern
the organisation and monitoring of logistic processes
(e.g. dispensing the right medication in the right dose to
the right patient); community pharmacists perform little
to no direct pharmaceutical patient care. As a result, phar-
macists have sparse experience in clinical pharmacother-
apy. Fourth, in the present system pharmacists and general
practitioners (GPs) have different responsibilities, back-
grounds and working processes, resulting in inadequate
collaboration [11]. Fifth, the present way of practicing of
both GPs and pharmacists is mainly reactive, while the
pharmaceutical care process requires a proactive approach.
Finally, there is a misfit between time-consuming nature of
performing medication reviews and the current workload
of both GPs and pharmacists.
Implementation of a non-dispensing pharmacist (NDP)
in primary care teams might address these implementa-
tion problems and improve outcomes of pharmaceutical
care. The NDP – as a healthcare team member – would
have access to patient records and the required clinical in-
formation. The lack of clinical knowledge and skills of the
pharmacist could be overcome by a training in clinical
pharmacy. Collaboration with the GP is expected to im-
prove, because the NDP is positioned into the clinical
practice and is a full member of the primary care team,
with the GP as head of the team. Furthermore, as the
NDP’s scope alters from drug product oriented to patient
oriented, the professional perspective will collide better
with that of the GP [12, 13]. Finally, this change in scope
relieves the NDP of his responsibility for the dispensing
process, and enables the NDP to work fulltime on the im-
provement of pharmacotherapy.
This model of integrated pharmaceutical care has
already been studied in Canada [14, 15], Australia [16]
and the United States of America [17]. It was found that
the model has the potential to address many of the bar-
riers to effective pharmaceutical care in the ways de-
scribed above, thereby optimising medication use and
hence leading to better healthcare outcomes [14, 16]. In
Canada, physicians recognised many interprofessional
benefits by working with a pharmacist directly inte-
grated into their practice. Also, benefits of improved
education were described [14]. The Australian study re-
ported a significant reduction in medication-related
problems after intervention by the pharmacists, and a
significant improvement of adherence to the medication
regimen [16]. In the USA, both GPs and patients per-
ceived qualitative benefits from the pharmacotherapy
consultations [17].
However, the ultimate benefit of this model for pa-
tients, namely the prevention of HARMs, has not been
demonstrated yet. Therefore, we designed the Pharma-
cotherapy Optimisation through Integration of a Non-
dispensing pharmacist in a primary care Team (POINT)
study, in which we assess, amongst others, the effect of a
non-dispensing pharmacist on medication-related hos-
pital admissions.
Methods
Design
The POINT study is a non-randomised, controlled inter-
vention study with pre-post comparison (see Table 1 for
a time schedule of the POINT study). Three different
Table 1 Time schedule of the POINT-study
Period Dates
Pre intervention period (1 year) 1st of January 2013 – 31st
of December 2013
Start-up period, prior to intervention
period (3 months)
1st of March 2014 – 31st of
May 2014
Intervention period (1 year) 1st of June 2014 – 31st of
May 2015
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models of pharmaceutical care provision in primary care
will be compared:
 Group A (intervention group): a GP practice with a
non-dispensing pharmacist based in the practice as
an integral member of the primary healthcare team;
 Group B (control group 1): ‘upgraded’ care as usual:
a GP practice collaborating with a dispensing pharmacist
based in a community pharmacy in the traditional
way, with the pharmacist having had a predefined,
certified additional training in reviewing medication,
 Group C (control group 2): care as usual: a GP practice
collaborating with a dispensing pharmacist based in a
community pharmacy in the traditional way.
A flowchart of the study design is shown in Fig. 1. Con-
currently, a qualitative implementation study is performed.
The protocol was peer-reviewed by the funding
organisation.
Setting
The project is implemented within primary care prac-
tices from the Julius General Practitioners Network
(University Medical Centre Utrecht) and the Academic
Network of General Practitioners (VU University Medical
Centre Amsterdam). These networks consist of more than
200 collaborating general practices.
Group A: selecting GPs, non-dispensing pharmacists and
matching both
General practices from the above mentioned networks
are all pro-actively invited to participate in the POINT
study. Ten general practices are selected, based on the
following criteria: willingness of the GPs to participate in
the project; willingness of the GPs to cooperate in the
development and evaluation of the role of the NDP;
minimum of 5000 registered patients; availability of an
office for a NDP, with access to the GP information sys-
tem; minimum of one practice nurse working on disease
management programs for chronic conditions such as
chronic obstructive pulmonary disease, diabetes, cardio-
vascular disease or mental health; healthcare centre
accredited by the Dutch College of General Practitioners
(NHG) [18]. The research collaboration is formalised in
a collaboration agreement.
Ten non-dispensing pharmacists are employed, using a
structured application procedure. All participating phar-
macists have a master degree in pharmacy (PharmD)
and preferably have working experience in providing
pharmaceutical care to individual patients. Furthermore,
Fig. 1 Flowchart of the study design. Abbreviations used: CPTP Clinical Pharmacy Training Program (newly developed for the intervention)
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in the selection procedure communication and collabor-
ation skills, as well as pharmacotherapy knowledge, em-
pathy, self-reflection skills and innovative attitude are
emphasized.
Subsequently, each NDP is posted in one of the ten se-
lected primary care centres in Utrecht or Amsterdam re-
gions. The NDPs work full time and exclusively in the
general practices, for a period of 15 months. The intro-
duction of such a new role in a healthcare practice is
complicated and faces a variety of challenges [14]. For
example, pharmacists need to be trained to fulfil their
new tasks, both pharmacists and GPs have to collaborate
closely and GPs have to explore the complementary role
of the NDP. Therefore, the first three months are used
as a start-up period before actually starting the interven-
tion period.
Group B and C: selecting GPs and collaborating
pharmacists
For both group B and C, ten general practices and
collaborating pharmacies are selected from the above-
mentioned networks as well. Criteria for participation
are comparable to those concerning the size of the prac-
tices, described for group A. In addition, characteristics
of patients of practices in groups B and C were matched
as far as possible with group A, considering age distribu-
tion and socioeconomic status. Subsequently, practices
and collaborating pharmacies are assigned to group B or
C, depending upon whether the collaborating pharma-
cists have completed a certified training program on per-
forming medication reviews in the Netherlands [19, 20],
or not, respectively. See Fig. 2.
Intervention
To improve the safety of pharmacotherapy within the gen-
eral practice, the intervention in group A by the NDPs
aims at two levels: individual patient consultation and
quality management on an organisational level. Herewith,
the NDPs are responsible for the medication management
and pharmaceutical care provided in the general practice.
The NDPs perform complementary work and do not take
over tasks of the GP nor the community pharmacist.
Individual patient consultation
The patient care process consists of an assessment of
the patient’s drug-related needs, a care plan to meet the
specific needs of the patient, and a follow-up evaluation
to determine the impact of the decisions made and ac-
tions taken. In practice, the NDP provides pharmaceut-
ical patient care for patients who are considered to be at
risk of adverse drug events, such as HARMs. These
patients, mostly of older age, with multimorbidity and
polypharmacy (chronic use of five or more medicines)
[1], are either pro-actively invited by the NDP or re-
ferred by the GP to discuss and review their medication.
Also, patients can make an appointment for a medication
Fig. 2 Overview of the selection criteria for general practices for group A, B and C
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assessment at their own request. During the first consult-
ation, which is preferably a home visit, the NDP will work
on a therapeutic relationship and interviews the patient to
gather information on the patient’s experiences with and
believes about medication, in order to assess his or her
drug-related needs. Questions concern the goal of therapy
for the patient, the current and past medication history,
adherence to the medication regimen and patient reported
medication issues. Afterwards, the NDP integrates the pa-
tient reported experiences and believes with the medical
status to determine whether there are potential drug ther-
apy problems. If necessary, the NDP provides recommen-
dations for optimisation of pharmacotherapy to the GP:
suggestions to stop, start or switch medication, to adjust
dosages, or for actions to improve adherence. These rec-
ommendations result in a documented individual pharma-
ceutical care plan, as part of the patient’s medical record.
The implementation of recommendations is monitored by
the NDP. Follow-up contacts can be conducted as a home
visit, a practice visit or by telephone.
Furthermore, the NDP covers other aspects of pharma-
ceutical patient care, such as individual consultations for
specific drug therapy problems or questions, and medica-
tion reconciliation in patients discharged from hospital.
All patient level interventions involve ongoing on-
location collaboration with the healthcare team – being
GP, practice nurses, assistants and the community phar-
macists. The NDP is available at the GP practice and has
daily formal and informal meetings with the GP in order
to establish individual pharmaceutical care plans and to
report on plans in progress. All members of the health-
care team can easily approach the NDP with questions
about medication and patients’ pharmacotherapy.
Quality management
The NDP aims to improve medication safety on an
organisational level, through optimisation of processes
within the practice around repeat prescribing, clinical
care paths, administrative efficiencies and identification
of common medication errors. The NDP is looking for
possible optimisation options in medication regimens,
such as monitoring renal function and electrolytes with
indicated pharmacotherapy, tapering the chronic use of
proton pump inhibitors, and optimising antibiotic pre-
scribing. Hereby, the NDP organises targeted programs
to improve the quality of pharmaceutical care in the
practice. Also, the NDP provides education of patients
and professionals involved.
Training program group A
To train the NDPs for their new role, a specialised Clin-
ical Pharmacy Training Program (CPTP) is developed,
based on workplace learning and the Canadian Medical
Education Directions for Specialists (CanMEDS) Roles
[21]. The CPTP started with a six-day training work-
shop, an internship in a nursing home and assignments
in practice. Plenary education days are gradually de-
creased and days in the general practice gradually in-
creased, ending with full time practice work with weekly
education days at the university. Key elements of the
training are consultation and communication skills,
clinical reasoning, clinical pharmacotherapy and being
reflective in practice. NDPs are trained to use a patient
centred approach in providing care, instead of a drug
product centred approach. Barriers to implementation
are discussed and ongoing support is provided through
structural intervision sessions and a mentorship and
buddy program [22].
Outcomes and measurements
Primary outcome: medication-related hospital admissions
(HARMs)
The primary outcome is the number of medication-
related hospital admissions (HARMs) in the high-risk
population. HARMs are defined as hospitalisations related
to adverse drug events. To identify these medication-
related hospital admissions, two pharmacists with clinical
experience will independently assess each hospitalisation
that occurred in the study population during follow-up,
using discharge information combined with the medical
and medication history. They will assess the causal rela-
tionship between the suspected medicine and the reason
for hospitalisation, according to an adjusted version of the
algorithm by Kramer et al. [23]. In this version, three
questions need to be answered (in contrast to six ques-
tions in the original algorithm): whether the reason for ad-
mission is known to be an adverse event of the suspected
medicine, whether alternative causes can explain the rela-
tionship between the suspected medicine and the adverse
event, and whether a plausible time relationship exists be-
tween the adverse event and the start of medication ad-
ministration (or the occurrence of the medication error).
On the basis of the answers, causality is classified as “pos-
sible”, “probable”, or “unlikely”. Cases with an assessment
of unlikely will be excluded.
Secondary outcomes
Potential medication errors The percentage of patients
with potential medication errors will be measured [24].
These potential medication errors mainly concern pre-
scription errors, such as under- and overprescribing and
dosage errors. Other potential medication errors might be
due to medication that is not or insufficiently effective, or
to inadequate monitoring of the effects of the therapy.
Also administration errors, such as non-adherence prob-
lems, will be measured as potential medication errors. A
complete list of included potential medication errors can
be found in Table 2.
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Drug burden index The drug burden index will be
calculated for every patient. This drug burden index
measures exposure to anticholinergic and sedative medi-
cation, and is associated with poorer physical and cogni-
tive performance in older people [25]. Hence, the drug
burden index can be seen as a proxy of drug therapy risk
and medication safety.
Costs A cost analysis will be performed, based upon
reimbursement data from databases of a Dutch major
health insurance company. Direct medical costs, such as
for medication, hospital care, specialist care, diagnostic
tests and other healthcare-related costs will be included.
Data collection
Data of all patients in groups A, B and C are accessible
through the routine health care databases of the Julius
General Practitioners Network (Utrecht) and the Aca-
demic Network of General Practitioners (Amsterdam).
After the intervention period (see Table 1), key data will
be extracted anonymously from the electronic medical
records in the general practices of both the pre- and
post-intervention period, through standard procedures
and existing algorithms. These data (see Table 2) are com-
bined with reimbursement data from the major healthcare
insurance company in the Utrecht and Amsterdam region,
obtaining 40-55 % of the reimbursement data of the re-
gion. No data will be obtained directly from patients.
Confounding factors
To be able to control for possible confounding, charac-
teristics of the involved general practices and pharmacies
in each group will be collected, using a questionnaire.
Additional information will be gathered about pharma-
ceutical care provision, the medication review protocol
used, the setting of the pharmacy and the general prac-
tice, the collaboration between the pharmacy and the
general practice and agreements on pharmaceutical care
provision.
Analyses and statistical method
All primary and secondary outcomes will be compared
in pre-post analyses and between groups comparisons
will be conducted. Descriptive statistics will be calcu-
lated for the baseline characteristics according to data of
the overall population in group A, B and C, as well as
for the high risk patients. The effect on the primary out-
come will be tested with logistic multilevel analysis. The
potential medication errors, drug burden index and costs
will be tested with mixed effect models. Baseline charac-
teristics can be integrated into the mixed effect models
to control for confounding.
Sample size calculation
With an expected prevalence of 4,5 % HARMs in
12 months within the high-risk population [26], we expect
an effect of 50 % reduction of HARMs [1]. To show a sta-
tistically significant difference between the intervention
group A and control group C, we include ten practices,
with a total of 45.000 patients, in each group. As 6,4 % of
patients in an average GP practice are part of the high risk
elderly population [26], this means that in each arm at
least 2850 high risk patients are included. This is based on
an alpha of 0,05 and a power (1-beta) of 0,8.
Table 2 Overview of outcomes, measurements and data sources
Outcomes Measurement Data sources
Primary outcome
Frequency of HARMs Number of HARMs DL, MH, MED
Secondary outcomes
Potential medication errors % patients with:
- medication not indicated MED/MR
- underprescribing MED/MR
- dosing error (too low or too high) MED/MR
- therapeutic duplication medication MED/MR
- medication contra-indicated MED/MR
- drug-drug interactions MED/MR
- medication not effective MED/MR
- inadequately monitored therapy MED/MR
- administration errors (e.g. non-adherence) MED/MR
Drug burden index Drug burden of medications with sedative and/or anticholinergic effects MR
Costs Medication costs and healthcare-related costs Database of insurance company
HARM hospital admission related to medication, DL discharge letter, MH medical history (with ICPC codes for diagnoses), MED medication records (including ATC
code, dose and strength), MR medical records (including laboratory markers and measurements such as blood pressure, pulse and body mass index)
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Qualitative study
In order to assess the feasibility of introducing a NDP in
general practice, parallel to the POINT study qualitative
data hereon is systematically collected. Semi-structured
interviews with participating GPs and NDPs are con-
ducted, and their views are described. Patients who are
seen by a NDP are asked about their perceptions and ex-
periences, using anonymised questionnaires. Hereby, con-
ditions that hinder or facilitate the introduction of a NDP
in general practice in the Netherlands may be identified.
Privacy and informed consent/Ethical approval
Based on the Dutch law for patient data protection, this
study was exempt of formal medical-ethical approval by
the Medical Ethical Committee University Medical Centre
Utrecht. (METC protocol number 13-432C).
Discussion
The POINT study aims to improve safety of pharmaco-
therapy in primary care, by introducing a non-dispensing
pharmacist as a member of the primary care team in the
Netherlands. This intervention aims to improve pharma-
ceutical care at both patient level and organisational level.
Therefore, it may be more effective than a singular
intervention, such as current medication reviews. A
comparison will be made with two existing models of
pharmaceutical care provision in primary care. This
comparison will demonstrate whether the introduction
of the NDP is more effective in improving the quality
and safety of pharmacotherapy than existing care
models.
Several methodological challenges were faced during
the design of the POINT study.
Choice for the design
Despite the fact that a randomised controlled trial is the
preferred design to evaluate the effect of an intervention,
we thoughtfully chose to use a non-randomised model.
In our opinion, willingness of all participating parties to
improve pharmaceutical patient care is a key condition
for the implementation of this intervention to succeed.
This has been recognised before, during the implemen-
tation of a pharmacist in primary care in Canada [14].
Therefore, general practices participating in the inter-
vention group of this study are selected instead of ran-
domly allocated to one of three research arms.
This selection, of course, has disadvantages. Once
proven effective, the broad implementation of this new
function might be challenging because of the high
standards we set for participating practices in this study.
In addition, selection of motivated general practices
might mask the effect of the intervention. As these
practices are motivated to improve pharmaceutical care,
standard pharmaceutical care might be better than
average beforehand, leaving little room for improvement.
By including pre-post analyses, we attempt to obviate
this problem.
Composition of the intervention
The introduction of the NDP is considered a complex
intervention. This is for intervening at different care
levels, as well as for integrating a new professional into
the primary work processes, which requires redistribution
of tasks and responsibilities around pharmacotherapeutic
care. Although the tasks of the NDP are predefined, the
actual implementation in the individual GP practices can-
not be protocolled: in order to increase the likelihood of a
successful implementation of the intervention, the inter-
vention has to be aligned to the needs of each participat-
ing centre. Consequently, the actual implementation of
the intervention itself may be heterogeneous. This can
blur quantitative measurements. Therefore, parallel to this
study, we conduct a qualitative study as described earlier.
With this study, we will list facilitators and barriers to the
implementation process, in order to assess the feasibility
of introducing a NDP in a complex healthcare setting in
daily practice.
Development of the clinical pharmacy training program
The clinical pharmacy training program (CPTP) has
been newly developed for the POINT study and has
neither been validated nor accredited. As the CPTP is
developed by experts in the field of education, based on
the theoretical frameworks of Vermunt, Kolb and Mer-
rienboer [27–29] and as it is embedded in the depart-
ment of vocational training for general practice, it is
expected to be an adequate postgraduate training for the
NDPs. Within the context of the POINT intervention
study, the program is evaluated and attuned on a struc-
tural basis.
Choice of the primary outcome measurement
In the context of ‘primum non nocere’ [30] the prime
aim of this study is to improve the safety of pharmaco-
therapy. Therefore, we chose reduction of medication-
related hospital admissions (HARMs), being a severe
adverse drug event, as primary outcome. This choice is,
however, challenging in several aspects.
First, the incidence of HARMs in primary care is low.
Although 5.6 % of acute hospital admissions are related
to medication [1], this accounts for only about 3.4
medication-related hospital admissions per GP on a yearly
basis – which means around 12–16 HARMs per partici-
pating practice in this study. In addition, we do have a
limited follow-up period of only one year. However, our
sample size calculation is based upon the occurence of
HARMs in a large group, so we expect this problem to
be adequately addressed. Last, measuring HARMs is
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challenging for quite detailed data have to be obtained
in order to determine HARMs. Causality assessments in
the POINT study will be based upon information of dis-
charge letters, which is limited information. However,
using this amount of information to determine HARMs
has been done before [31]. Also, we do have experience
from previous studies [1, 26] and will use a validated
method to identify the primary outcome parameter.
Availability of data for secondary outcome measurements
To correctly measure and analyse the secondary outcomes,
the required data need to be properly documented in the
GPs’ information systems. Due to the heterogeneous study
setting we are dependent on the diverse working methods
of the participating healthcare providers. As this possible
loss of information will show equally in each research arm,
we expect this will not influence our study results.
The cost evaluation performed in this study will yield
an insight in the direct medical costs of each model of
pharmaceutical care provision in primary care. For this
evaluation, a subgroup of patients will be analysed, as
data of the insurance company will not be available for
all patients. A full economic evaluation including a soci-
etal costs and economic modelling is outside the scope
of this research project.
Conclusion
This study will provide information as to whether the
integration of a non-dispensing pharmacist in primary
care will improve medication safety compared to current
care models.
Abbreviations
HARM: Hospital Admission Related to Medication; GP: General Practitioner;
NDP: Non-Dispensing Pharmacist; POINT: Pharmacotherapy Optimisation
through Integration of a Non-dispensing pharmacist in a primary care Team;
CPTC: Clinical Pharmacy Training Program.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AJL, DLMZ, AdB, MB, JJdG and NJW participated in the design of the trial
and study methodology. ACMH and VMS (both PhD candidates), AJL and
DLMZ participated in the manuscript preparation and ACMH has an ongoing
role in carrying out the trial. NJW and MLB reviewed the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
The POINT-project is funded by The Netherlands Organisation for Health
Research and Development (ZonMW). Implementation of NDPs was
supported by the Dutch health insurance company Agis/Achmea.
Author details
1Department of General Practice, Julius Centre for Health Sciences and
Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands.
2Institute of Health Policy and Management, Erasmus University Rotterdam,
Rotterdam, The Netherlands. 3Department of Pharmaceutical Sciences,
Utrecht University, Utrecht, The Netherlands. 4Department of
Pharmacotherapy and Pharmaceutical Care, University of Groningen,
Groningen, The Netherlands.
Received: 1 June 2015 Accepted: 15 June 2015
References
1. Leendertse AJ, Egberts ACG, Stoker LJ, van den Bemt PMLA. Frequency of
and risk factors for preventable medication-related hospital admissions in
the Netherlands. Arch Intern Med. 2008;168:1890–6.
2. Denneboom W, Dautzenberg MG, Grol R, de Smet PA. Treatment reviews of
older people on polypharmacy in primary care: cluster controlled trial
comparing two approaches. Br J Gen Pract. 2007;57:723–31.
3. Kwint HF, Faber A, Gussekloo J, Bouvy ML. Effects of medication review on
drug-related problems in patients using automated drug-dispensing
systems: a pragmatic randomized controlled study. Drugs Aging.
2011;28:305–14.
4. Stuijt CC, Franssen EJ, Egberts AC, Hudson SA. Appropriateness of
prescribing among elderly patients in a Dutch residential home:
observational study of outcomes after a pharmacist-led medication review.
Drugs Aging. 2008;25:947–54.
5. Vinks TH, Egberts TC, de Lange TM, de Koning FH. Pharmacist-based
medication review reduces potential drug-related problems in the elderly:
the SMOG controlled trial. Drugs Aging. 2009;26:123–33.
6. Kempen TG, van de Steeg-van Gompel CH, Hoogland P, Liu Y, Bouvy ML.
Large scale implementation of clinical medication reviews in Dutch
community pharmacies: drug-related problems and interventions. Int J Clin
Pharm. 2014;36:630–5.
7. Chau SH, Jansen APD, van de Ven PM, Hoogland P, Elders PJM, Hugtenburg
JG. Medicatiebeoordelingen in de openbare apotheek: prevalentie van
geneesmiddelgerelateerde problemen bij ouderen met polyfarmacie en
inzicht in patiënt-, behaldelings- en ziektegerelateerde factoren. PW
Wetenschappelijk Platform. 2014;8:a1428.
8. Leendertse AJ. Dissertation: Hospital admissions related to medication:
prevalence, provocation and prevention. Chapter 3.2 The effect of a
pharmaceutical care process intervention on medication-related hospital
admissions in the elderly in an integrated primary care setting: results of
the PHARM study, Appendix "The discrepancy between intended and actual
number of included patients in the PHARM-study". p. 159-62.
9. Edmunds J, Calnan MW. The reprofessionalisation of community pharmacy?
An exploration of attitudes to extended roles for community pharmacists
amongst pharmacists and General Practioners in the United Kingdom. Soc
Sci Med. 2001;53:943–55.
10. Farris KB, Côté I, Feeny D, Johnson JA, Tsuyuki RT, Brilliant S, Dieleman S.
Enhancing primary care for complex patients. Demonstration project using
multidisciplinary teams. Can Fam Physician. 2004;50:998–1003.
11. Kwint HF, Bermingham L, Faber A, Gussekloo J, Bouvy ML. The relationship
between the extent of collaboration of general practitioners and
pharmacists and the implementation of recommendations arising from
medication review: a systematic review. Drugs Aging. 2013;30:91–102.
12. McDonough RP, Doucette WR. Dynamics of pharmaceutical care:
developing collaborative working relationships between pharmacists and
physicians. J Am Pharm Assoc. 2001;41:682–92.
13. D'Amour D, Ferrada-Videla M, San Martin Rodriguez L, Beaulieu MD. The
conceptual basis for interprofessional collaboration: core concepts and
theoretical frameworks. J Interprof Care. 2005;19 Suppl 1:116–31.
14. Dolovich L, Pottie K, Kaczorowski J, Farrell B, Austin Z, Rodriguez C, Gaebel
K, Sellors C. Integrating family medicine and pharmacy to advance primary
care therapeutics. Clin Pharmacol Ther. 2008;83:913–7.
15. Hogg W, Lemelin J, Dahrouge S, Liddy C, Armstrong CD, Legault F, Dalziel
B, Zhang W. Randomized controlled trial of anticipatory and preventive
multidisciplinary team care. Can Fam Physician. 2009;55:e76–85.
16. Tan ECK, Stewart K, Elliott RA, George J. Pharmacist consultations in general
practice clinics: The Pharmacists in Practice Study (PIPS). Res Social Adm
Pharm. 2013:1–11.
17. Jameson JP, VanNoord GR. Pharmacotherapy consultation on polypharmacy
patients in ambulatory care. Ann Pharmacother. 2001;35:835–40.
18. NHG: Nederlands Huisartsen Genootschap. https://www.nhg.org/ Accessed
19 June 2015.
19. Periodieke Individuele Analyse Farmacotherapie (PIAF). http://www.
paofarmacie.nl/uploads/files/folder_PIAF_def.pdf Accessed 19 June 2015.
20. Service Apotheek Farmacotherapie Expert opleiding. http://
www.serviceapotheeknascholing.net/ Accessed 19 June 2015.
Hazen et al. BMC Family Practice  (2015) 16:76 Page 8 of 9
21. CanMEDS: better standards, better physicians, better care. http://
www.royalcollege.ca/portal/page/portal/rc/resources/aboutcanmeds.
Accessed 19 June 2014.
22. Balint M. The doctor, his patient and the illness. 1st ed. London: Pitman
Medical Publishing; 1964.
23. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR. An algorithm for the
operational assessment of adverse drug reactions. I. Background,
description, and instructions for use. JAMA. 1979;242:623–32.
24. Schumock GT, Thornton JP. Focusing on the preventability of adverse drug
reactions. Hosp Pharm. 1992;27:538.
25. Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham G, Harris TB,
Hanlon JT, Rubin SM, Shorr RI, Bauer DC, Abernethy DR. A drug burden
index to define the functional burden of medications in older people. Arch
Intern Med. 2007;167:781–7.
26. Leendertse AJ, de Koning FHP, Goudswaard AN, Belitser SV, Verhoef M, de
Gier HJ, Ebgerts TCG, van den Bemt PMLA. Preventing hospital admissions
by reviewing medication (PHARM) in primary care: an
open controlled study in an elderly population. J Clin Pharm Ther.
2013;38:379–87.
27. Vermunt JD, Verloop N. Congruence and friction between learning and
teachingCongruence and friction between learning and teaching. Learn
Instr. 1999;9:257–280.
28. Kolb DA. The process of experiential learning. In: Kolb DA, editor.
Experiential learning: experience as the source of learning and development.
Englewood Cliffs, New Jersey: Prentice Hall Inc.; 1984. p. 20–38.
29. van Merriënboer JJG. Training complex cognitive skills: a four component
instructional design model for technical training. Englewood Cliffs, New
Jersey: Educational Technology; 1997.
30. Nederlandse artseneed. http://knmg.artsennet.nl/Publicaties/KNMG
publicatie/62487/Nederlandse-artseneed-inclusief-Eed-van-Hippocrates-
Verklaring-van-Geneve-2004.htm Accessed 19 June 2015.
31. van der Hooft CS, Dieleman JP, Siemes C, Aarnoudse AJ, Verhamme KM,
Stricker BH, Sturkenboom MC. Adverse drug reaction-related hospitalisations: a
population-based cohort study. Pharmacoepidemiol Drug Saf. 2008;17:365–71.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hazen et al. BMC Family Practice  (2015) 16:76 Page 9 of 9
